Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giorgio Zauli

Showing results (1-10 of 215) with videos related to

Pageof 22
Sort By:
Cytokine & Growth Factor Reviews|June 6, 2006
The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biologyGiorgio Zauli, Paola Secchiero
Current Opinion in Hematology|November 29, 2007
Tumor-necrosis-factor-related apoptosis-inducing ligand and the regulation of hematopoiesisPaola Secchiero, Giorgio Zauli
Journal of Cellular Physiology|September 25, 2004
Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2LRoberta Di Pietro, Giorgio Zauli
Investigational New Drugs|October 12, 2012
The non-genotoxic activator of the p53 pathway Nutlin-3 shifts the balance between E2F7 and E2F1 transcription factors in leukemic cellsMaria Grazia di Iasio, Giorgio Zauli
Acta Bio-Medica : Atenei Parmensis|May 1, 2007
A role of the TRAIL-TRAIL receptor system in the pathogenesis of diabetesMauro Vaccarezza, Giorgio Delbello, Giorgio Zauli
Expert Opinion on Therapeutic Targets|May 10, 2011
Molecular targets for selective killing of TRAIL-resistant leukemic cellsGiorgio Zauli, Raffaella Bosco, Paola Secchiero
Recent Patents on Anti-Cancer Drug Discovery|November 26, 2011
State of art and recent developments of anti-cancer strategies based on TRAILStella Bernardi, Paola Secchiero, Giorgio Zauli
Human Immunology|March 1, 2012
The MDM2 inhibitor Nutlin-3 modulates dendritic cell-induced T cell proliferationChiara Gasparini, Alberto Tommasini, Giorgio Zauli
Current Pharmaceutical Design|March 12, 2011
Recent advances in the therapeutic perspectives of Nutlin-3Paola Secchiero, Raffaella Bosco, Claudio Celeghini, et al.
Molecular Carcinogenesis|November 30, 2012
Selective induction of TP53I3/p53-inducible gene 3 (PIG3) in myeloid leukemic cells, but not in normal cells, by Nutlin-3Rebecca Voltan, Paola Secchiero, Federica Corallini, et al.
Pageof 22

Showing results (1-10 of 215) with videos related to

Sort By:
Pageof 22
Cytokine & Growth Factor Reviews|June 6, 2006
The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biologyGiorgio Zauli, Paola Secchiero
Current Opinion in Hematology|November 29, 2007
Tumor-necrosis-factor-related apoptosis-inducing ligand and the regulation of hematopoiesisPaola Secchiero, Giorgio Zauli
Journal of Cellular Physiology|September 25, 2004
Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2LRoberta Di Pietro, Giorgio Zauli
Investigational New Drugs|October 12, 2012
The non-genotoxic activator of the p53 pathway Nutlin-3 shifts the balance between E2F7 and E2F1 transcription factors in leukemic cellsMaria Grazia di Iasio, Giorgio Zauli
Acta Bio-Medica : Atenei Parmensis|May 1, 2007
A role of the TRAIL-TRAIL receptor system in the pathogenesis of diabetesMauro Vaccarezza, Giorgio Delbello, Giorgio Zauli
Expert Opinion on Therapeutic Targets|May 10, 2011
Molecular targets for selective killing of TRAIL-resistant leukemic cellsGiorgio Zauli, Raffaella Bosco, Paola Secchiero
Recent Patents on Anti-Cancer Drug Discovery|November 26, 2011
State of art and recent developments of anti-cancer strategies based on TRAILStella Bernardi, Paola Secchiero, Giorgio Zauli
Human Immunology|March 1, 2012
The MDM2 inhibitor Nutlin-3 modulates dendritic cell-induced T cell proliferationChiara Gasparini, Alberto Tommasini, Giorgio Zauli
Current Pharmaceutical Design|March 12, 2011
Recent advances in the therapeutic perspectives of Nutlin-3Paola Secchiero, Raffaella Bosco, Claudio Celeghini, et al.
Molecular Carcinogenesis|November 30, 2012
Selective induction of TP53I3/p53-inducible gene 3 (PIG3) in myeloid leukemic cells, but not in normal cells, by Nutlin-3Rebecca Voltan, Paola Secchiero, Federica Corallini, et al.
Pageof 22